A CDC analysis of Antimicrobial Resistance Laboratory Network data found pediatric carbapenemase-producing CRE incidence in the United States rose 92% from 2019 to 2024, driven mostly by NDM-producing organisms.
|Videos|November 12, 2017
Exploring the Societal Value of Antibiotics
Author(s)Contagion® Editorial Staff
Glenn Tillotson, PhD, FIDSA, discusses the societal value of antibiotics.
Advertisement
Glenn Tillotson, PhD, FIDSA, consultant microbiologist in Durham, NC, discusses the societal value of antibiotics.
Interview Transcript (modified slightly for readability):
“The societal value of antibiotics is something that is only just beginning to be appreciated. An infection, in reality, doesn’t just affect the individual patient; sometimes it’s a population effect in terms of, the spread of disease; there’s the impact on a hospital system, maybe there is an infection control issue. And so, there are many, many aspects of and infection, and therefore, that should be attributed to an antibiotic. And, at the moment, I don’t think people appreciate that societal value.”
Advertisement
Related to this article
Here is a case that was linked to a unique travel history and led to a series of acute health issues.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with SAB. This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline. Here is a closer look at Consensus Statement 2: Follow-up Blood Cultures.
IDSA and ESCMID released 7 consensus statements to assist in managing individuals with Staphylococcus aureus Bacteremia (SAB). This review will focus on the adult patient population and additional information on pediatric population statements can be assessed in the guideline.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Recent urinary tract infection guideline updates from multiple international
medical societies highlight evolving recommendations, including a major shift
in classification, moving from anatomy- and risk factor–based definitions
toward distinguishing localized from systemic infections.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
In a national survey of 959 US adults, 27.9% said they had exaggerated or made up symptoms to obtain antibiotics, most often cold-like symptoms, with implications for outpatient stewardship.
Advertisement
Advertisement
Trending on Contagion Live
1
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
2
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
3
CDC: NDM Drives 92% Rise in Carbapenemase-Producing CRE Among US Children
4
A Portal–Systemic Infectious Cascade: Invasive Amoebiasis Leading to Septic Portal Vein Thrombosis and Endocarditis
5